KRON Kronos Bio

Kronos Bio Announces Participation in H.C. Wainwright 24th Annual Global Investment Conference

Kronos Bio Announces Participation in H.C. Wainwright 24th Annual Global Investment Conference

SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced participation in the H.C. Wainwright 24th Annual Global Investment Conference. An on-demand webcast of the presentation will be available on Monday, September 12, 2022, at 7 a.m. ET.

The webcast will be available on the Investors and Media section of the Kronos Bio website at . A replay of the webcast will be archived and available for 30 days following the event.

About Kronos Bio, Inc.

Kronos Bio is a biopharmaceutical company that is advancing three investigational compounds in clinical trials for patients with cancer. The company’s lead compound, the SYK inhibitor entospletinib, is being evaluated in the registrational Phase 3 AGILITY trial as a treatment for patients with newly diagnosed NPM1-mutated acute myeloid leukemia (AML). The company is also developing the CDK9 inhibitor, KB-0742, as a treatment for MYC-amplified solid tumors and lanraplenib, a next-generation SYK inhibitor being assessed in patients with FLT3-mutated AML. The company’s scientific focus is on developing medicines that target the dysregulated transcription that is the hallmark of cancer and other serious diseases.

Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit or follow the company on LinkedIn.

Company Contact:

Marni Kottle

Kronos Bio

650-900-3450

Investors:

Claudia Styslinger

Argot Partners

212-600-1902

Media:

Sheryl Seapy

Real Chemistry

949-903-4750

 



EN
06/09/2022

Underlying

KRONKronos Bio

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kronos Bio

 PRESS RELEASE
Free
KRON KRONOS BIO

Kronos Bio Enters into Agreement to Be Acquired by Concentra Bioscienc...

Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. ("Kronos Bio") (Nasdaq: KRON), a biotechnology company that has been developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Concentra Biosciences, LLC ( “Concentra”), whereby Concentra will acquire Kronos Bio for $0.57 in cash per share...

May 1, 2025 1 EN
 PRESS RELEASE
Free
KRON KRONOS BIO

Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial results. Fourth Quarter and Full Year 2024 Financial Results Cash, cash equivalents and investments: Cash, cash equivalents and investments as of December 31, 2024, were $112.4 million.R&D Expenses: Research and development expenses were $8.4 million for the fourth quarter of 2024, which includes non-cash stock-based co...

March 18, 2025 1 EN
 PRESS RELEASE
Free
KRON KRONOS BIO

Kronos Bio Announces CEO Transition and Reduction in Force

Kronos Bio Announces CEO Transition and Reduction in Force – Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman, Ph.D., COO & CFO, is named President & Interim CEO – SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that its Board of Directors has appointed Deborah Knobelman, Ph.D., as President and Interim Chief Executive Officer, effective D...

November 27, 2024 1 EN
 PRESS RELEASE
Free
KRON KRONOS BIO

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors R...

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 – Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo models at well tolerated exposures – SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcrip...

November 14, 2024 1 EN
 PRESS RELEASE
Free
KRON KRONOS BIO

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate ...

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives – Discontinuing development of istisociclib, a CDK9 inhibitor; benefit-risk profile in platinum-resistant high-grade serous ovarian cancer does not support further development – – Kronos Bio Board of Directors has approved plan to evaluate strategic alternatives to maximize stockholder value – – Kronos Bio’s additional pipeline assets include preclinical p300 KAT inhibitor programs in oncology and autoimmune disease – — $124.9 million cash, cash equivalents, and...

November 13, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch